44 related articles for article (PubMed ID: 23489237)
21. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
22. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
24. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
26. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
27. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.
Martino M; Laszlo D; Lanza F
Expert Opin Biol Ther; 2014 Jun; 14(6):757-72. PubMed ID: 24597960
[TBL] [Abstract][Full Text] [Related]
28. [Hematopoietic growth factors and autologous or allogeneic stem cell transplantation].
Bay JO; Peffault de Latour R; Tournilhac O; Choufi B; Chassagne J
Bull Cancer; 2006 May; 93(5):473-82. PubMed ID: 16777625
[TBL] [Abstract][Full Text] [Related]
29. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
Sourgens H; Lefrère F
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
[TBL] [Abstract][Full Text] [Related]
31. [Hematopoietic stem cells mobilization: state of the art in 2011 and perspectives].
Bijou F; Ivanovic Z; Boiron JM; Nicolini F
Transfus Clin Biol; 2011 Dec; 18(5-6):503-15. PubMed ID: 22019608
[TBL] [Abstract][Full Text] [Related]
32. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature.
Shaughnessy P; Chao N; Shapiro J; Walters K; McCarty J; Abhyankar S; Shayani S; Helmons P; Leather H; Pazzalia A; Pickard S
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1301-9. PubMed ID: 23685251
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte colony stimulating factors: how different are they? How to make a decision?
Martin-Christin F
Anticancer Drugs; 2001 Mar; 12(3):185-91. PubMed ID: 11290864
[TBL] [Abstract][Full Text] [Related]
34. Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review.
Markovic U; Colarossi C; Iuppa A; Scire P; Gorgone A; Galbo F; Amato G; Moschetti G
J Int Med Res; 2022 May; 50(5):3000605221095504. PubMed ID: 35638556
[TBL] [Abstract][Full Text] [Related]
35. Comparing the effectiveness of biosimilar filgrastim (Nivestim®) versus original filgrastim (Neupogen®) for stem cell mobilization in adult and pediatric healthy donors.
Muffarrej D; Hashem H; Tbakhi A; Najjar R
J Oncol Pharm Pract; 2023 Jun; ():10781552231171829. PubMed ID: 37357617
[TBL] [Abstract][Full Text] [Related]
36. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors.
Pérez-López O; Martín-Sánchez J; Parody-Porras R; Espigado-Tocino I; Noguerol P; Carmona-González M; Pérez-Simón JA
Transfusion; 2013 Dec; 53(12):3240-2. PubMed ID: 23489237
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
